Share on StockTwits

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to issue its Q114 quarterly earnings data on Friday, April 25th. Analysts expect the company to announce earnings of $0.87 per share and revenue of $361.58 million for the quarter. IDEXX Laboratories has set its FY14 guidance at $3.82-3.92 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.81 by $0.01. The company had revenue of $354.10 million for the quarter, compared to the consensus estimate of $347.08 million. During the same quarter in the prior year, the company posted $0.78 earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $3.83 EPS for the current fiscal year and $4.37 EPS for the next fiscal year.

IDEXX Laboratories (NASDAQ:IDXX) opened at 119.88 on Thursday. IDEXX Laboratories has a 1-year low of $81.57 and a 1-year high of $129.27. The stock’s 50-day moving average is $122.5 and its 200-day moving average is $113.. The company has a market cap of $6.186 billion and a price-to-earnings ratio of 34.12.

A number of analysts have recently weighed in on IDXX shares. Analysts at Stifel Nicolaus raised their price target on shares of IDEXX Laboratories from $120.00 to $135.00 in a research note on Monday, April 14th. They now have a “buy” rating on the stock. On a related note, analysts at Piper Jaffray initiated coverage on shares of IDEXX Laboratories in a research note on Monday, March 10th. They set a “neutral” rating and a $125.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of IDEXX Laboratories from $99.00 to $116.00 in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $117.75.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.